Pre-clinical studies of human lung and prostate cancers:
Studies of autocrine growth factors (neuropeptides and antagonists) in
signal transduction
and apoptotic pathways of human lung cancer.
Development of peptide antagonists and anti-angiogeneic agents for the
treatment of human lung and prostate cancers.
Development of small mimetic molecules for cancer therapy.
Combined chemotherapy, radiation, immunotherapy and chemoprevention in
vivo.
Pre-clinical efficacious studies: development of subcutaneous and
orthotopic tumor models (lung, prostate, breast, renal, colon cancers) in
small animals and in vivo efficacious studies of therapeutic agents.
Targeted therapy using stealth liposomes, immunoconjugates and
immunoliposomes.
Nanotechnology:
Development of magnetic nanoparticles (superparamagnetic iron oxides) for
diagnostic applications (as contrast agents in magnetic resonance imaging )
Development of magnetic nanoparticles including ferroimmunoconjugates,
magnetoliposomes, immuno-magnetoliposomes for therapeutic applications (as
drug carriers , gene delivery and magnetic fluid hyperthermia).
Development of targetable immuno-liposomes, novel cationic lipids and
biolistic process for gene delivery, drug delivery and macromolecule
delivery
To top of page